PURPOSE: To determine the impact of age and health status on adjuvant treatment recommendations for older patients with breast cancer from the perspective of medical oncologists and primary care physicians with geriatric expertise. PATIENTS AND METHODS: One hundred fifty-one oncologists and 158 primary care physicians with geriatric expertise participated in an online survey. The survey described hypothetical patients of varying ages (70, 75, 80, and 85 years) and health status (good, average, and poor) who had node-positive, hormone receptor-positive, human epidermal growth factor receptor 2 (HER-2)/neu-negative; and hormone receptor-negative, HER-2/neu-positive breast cancers. The effects of patient age and health status on the survey participants' adjuvant treatment recommendations were examined using generalized estimation equation methods. RESULTS: The majority of both oncologists and primary care physicians recommended some form of adjuvant therapy for patients of all ages (70, 75, 80, and 85 years) and health status. Both oncologists and primary care providers were less likely to recommend adjuvant treatment as a patient's age increased or health status declined (P < .0001). There were no significant differences in treatment recommendations among primary care physicians and oncologists for patients with hormone receptor-negative, HER-2/neu-positive tumors (P = .54). However, primary care providers were more likely than oncologists to recommend no adjuvant treatment for patients age 75 years or older with hormone receptor-positive, HER-2/neu-negative tumors (P < .01). CONCLUSION: Age and health status influence oncologists' and primary care providers' adjuvant treatment recommendations. Evidence-based guidelines for breast cancer treatment in older adults taking into account age and health status are needed.
PURPOSE: To determine the impact of age and health status on adjuvant treatment recommendations for older patients with breast cancer from the perspective of medical oncologists and primary care physicians with geriatric expertise. PATIENTS AND METHODS: One hundred fifty-one oncologists and 158 primary care physicians with geriatric expertise participated in an online survey. The survey described hypothetical patients of varying ages (70, 75, 80, and 85 years) and health status (good, average, and poor) who had node-positive, hormone receptor-positive, humanepidermal growth factor receptor 2 (HER-2)/neu-negative; and hormone receptor-negative, HER-2/neu-positive breast cancers. The effects of patient age and health status on the survey participants' adjuvant treatment recommendations were examined using generalized estimation equation methods. RESULTS: The majority of both oncologists and primary care physicians recommended some form of adjuvant therapy for patients of all ages (70, 75, 80, and 85 years) and health status. Both oncologists and primary care providers were less likely to recommend adjuvant treatment as a patient's age increased or health status declined (P < .0001). There were no significant differences in treatment recommendations among primary care physicians and oncologists for patients with hormone receptor-negative, HER-2/neu-positive tumors (P = .54). However, primary care providers were more likely than oncologists to recommend no adjuvant treatment for patients age 75 years or older with hormone receptor-positive, HER-2/neu-negative tumors (P < .01). CONCLUSION: Age and health status influence oncologists' and primary care providers' adjuvant treatment recommendations. Evidence-based guidelines for breast cancer treatment in older adults taking into account age and health status are needed.
Authors: P Narain; L Z Rubenstein; G D Wieland; B Rosbrook; L S Strome; F Pietruszka; J E Morley Journal: J Am Geriatr Soc Date: 1988-09 Impact factor: 5.562
Authors: Joy H Lewis; Meredith L Kilgore; Dana P Goldman; Edward L Trimble; Richard Kaplan; Michael J Montello; Michael G Housman; José J Escarce Journal: J Clin Oncol Date: 2003-04-01 Impact factor: 44.544
Authors: Karim Malek; Aliza K Fink; Soe Soe Thwin; Jerry Gurwitz; Patricia A Ganz; Rebecca A Silliman Journal: Med Care Date: 2004-07 Impact factor: 2.983
Authors: Ajeet Gajra; Heidi D Klepin; Tao Feng; William P Tew; Supriya G Mohile; Cynthia Owusu; Cary P Gross; Stuart M Lichtman; Tanya M Wildes; Andrew E Chapman; Efrat Dotan; Vani Katheria; Laura Zavala; Chie Akiba; Arti Hurria Journal: J Geriatr Oncol Date: 2015-02-07 Impact factor: 3.599
Authors: Arti Hurria; Kayo Togawa; Supriya G Mohile; Cynthia Owusu; Heidi D Klepin; Cary P Gross; Stuart M Lichtman; Ajeet Gajra; Smita Bhatia; Vani Katheria; Shira Klapper; Kurt Hansen; Rupal Ramani; Mark Lachs; F Lennie Wong; William P Tew Journal: J Clin Oncol Date: 2011-08-01 Impact factor: 44.544
Authors: A Schwandt; P J Harris; S Hunsberger; A Deleporte; G L Smith; D Vulih; B D Anderson; S P Ivy Journal: Clin Cancer Res Date: 2014-07-15 Impact factor: 12.531
Authors: Katherine E Reeder-Hayes; John Bainbridge; Anne Marie Meyer; Keith D Amos; Bryan J Weiner; Paul A Godley; William R Carpenter Journal: Breast Cancer Res Treat Date: 2011-02-22 Impact factor: 4.872